

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RELTON *et al.*

Appl. No.: *To Be Assigned* (U.S. Nat'l Phase
of PCT/US2005/002535; Int'l Filing Date:
January 28, 2005)

Filed: *Herewith* (July 28, 2006)

For: **Treatment of Conditions Involving
Dopaminergic Neuronal Degeneration
Using Nogo Receptor Antagonists**

Confirmation No.: *To Be Assigned*

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2159.0450001/EJH/SAC

Preliminary Amendment Under 37 C.F.R. § 1.115

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments to the Specification begin on page 2

Remarks begin on page 3